Drug intelligence / Profile preview

tenofovir alafenamide tartrate

Development stage: Approved
Lead developer: Haisco Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HEISCO-149 is a small molecule nucleotide reverse transcriptase inhibitor (NRTI) developed by Sichuan Haisco Pharmaceutical. It is a tartrate salt formulation of tenofovir alafenamide (TAF), designed as a generic alternative or improved formulation of tenofovir alafenamide fumarate (Vemlidy). The drug is primarily indicated for the treatment of chronic hepatitis B virus (HBV) infection. Its mechanism of action involves the inhibition of HBV DNA polymerase, which prevents the replication of the viral genome. Compared to older tenofovir formulations, TAF-based drugs like HEISCO-149 offer high antiviral potency at lower doses, resulting in reduced systemic exposure to tenofovir and a more favorable safety profile regarding renal and bone toxicity.

Other names: tenofovir alafenamide tartrate

Targets

HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on tenofovir alafenamide tartrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tenofovir alafenamide tartrate.

Explore the full profile